"10.1371_journal.pone.0083190","plos one","2013-12-31T00:00:00Z","Kevin G McLure; Emily M Gesner; Laura Tsujikawa; Olesya A Kharenko; Sarah Attwell; Eric Campeau; Sylwia Wasiak; Adam Stein; Andre White; Eric Fontano; Robert K Suto; Norman C W Wong; Gregory S Wagner; Henrik C Hansen; Peter R Young","Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America; Xtal BioStructures Inc., Natick, Maryland, United States of America","Conceived and designed the experiments: KGM EMG LT OAK SA EC RKS PRY. Performed the experiments: EMG LT OAK SA EC SW AS EF. Analyzed the data: KGM EMG LT OAK SA EC SW AS AW EF RKS NCW GSW PRY. Contributed reagents/materials/analysis tools: HCH. Wrote the paper: PRY KGM RKS.","Authors affiliated with Resverlogix receive salary from and stock options in Resverlogix. Authors affiliated with Xtal BioStructures were compensated by Resverlogix for work performed. HCH is an inventor on RVX-208 composition of matter patents. KGM and PRY are inventors on patent applications for method of use of Resverlogix BET inhibitors for Treatment of Diseases by Epigenetic Regulation. The relevant United States patent is United States 8,053,440 with HCH as inventor. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","12","Kevin G McLure","KGML",15,TRUE,8,8,14,3,TRUE,TRUE,FALSE,0,NA,FALSE
